Story perspectives

Repatha Cuts Heart Attack Risk by 36%, FDA Approves

11/8/2025

23 2

Summary

Story summary

A study at the American Heart Association meeting found that Amgen's cholesterol drug, Repatha, reduced major cardiovascular events by 25% in at-risk patients without prior heart attacks or strokes.
The trial included over 12,000 patients and demonstrated a 36% reduction in the risk of a first heart attack.
The FDA expanded Repatha's approval for adults with high LDL cholesterol, regardless of previous cardiovascular disease.
Repatha's sales reached $2.15 billion in the first nine months of 2025.
Merck is developing a competing oral PCSK9 drug, with data to be presented at the meeting.

1 of 1

Story summary

A study at the American Heart Association meeting found that Amgen's cholesterol drug, Repatha, reduced major cardiovascular events by 25% in at-risk patients without prior heart attacks or strokes.
The trial included over 12,000 patients and demonstrated a 36% reduction in the risk of a first heart attack.
The FDA expanded Repatha's approval for adults with high LDL cholesterol, regardless of previous cardiovascular disease.
Repatha's sales reached $2.15 billion in the first nine months of 2025.
Merck is developing a competing oral PCSK9 drug, with data to be presented at the meeting.